Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- 4 April 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 393 (10183), 1819-1830
- https://doi.org/10.1016/s0140-6736(18)32409-7
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRThe New England Journal of Medicine, 2010
- First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic ReviewJournal of Thoracic Oncology, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung CancerClinical Cancer Research, 2008
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2006
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2002
- Group sequential designs using a family of type I error probability spending functionsStatistics in Medicine, 1990
- Comparative analysis of two ratesStatistics in Medicine, 1985
- The Efficiency of Cox's Likelihood Function for Censored DataJournal of the American Statistical Association, 1977